癌症生物標記市場規模、佔有率、成長分析（按分析技術、按癌症類型、按產品、按應用、按最終用戶、按地區）—2025 年至 2032 年行業預測

2023 年癌症生物標記市場規模價值 271 億美元，預計將從 2024 年的 304.9 億美元成長到 2032 年的 782.2 億美元，預測期內（2025-2032 年）的複合年成長率為 12.5%。

受全球癌症發生率上升和腫瘤學研究投入增加的推動，全球癌症生物標記市場預計將顯著成長。人們越來越意識到癌症生物標記在提高診斷準確性和治療效果方面的關鍵作用，並有望為該領域的公司開闢新的途徑。此外，個人化醫療和基因治療的日益成長的趨勢預計將進一步促進癌症生物標記的使用。技術進步，加上對非侵入性和微創方法的偏好，可能會創造更多的機會。然而，對臨床有效性的擔憂、醫療保健專業人員的認知有限、道德問題以及嚴格的監管環境等挑戰可能會在未來幾年限制市場的發展。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管分析

癌症生物標記市場規模（依分析技術及複合年成長率） (2025-2032)

• 市場概覽
• 體學技術
  • 蛋白質體學
  • 免疫檢測
  • 質譜法
  • 2D凝膠電泳
  • 蛋白質微陣列
  • 其他
  • 基因組學
  • 次世代定序
  • 聚合酵素鏈鎖反應
  • 原位雜合技術
  • 其他
• 影像技術
  • 超音波影像
  • 電腦斷層掃描
  • 磁振造影
  • 正子斷層掃描
  • 乳房X光檢查

癌症生物標記市場規模（按癌症類型和複合年成長率） (2025-2032)

• 市場概覽
• 乳癌
• 肺癌
• 大腸直腸癌
• 攝護腺癌
• 黑色素瘤
• 白血病
• 甲狀腺癌
• 膀胱癌
• 非何傑金氏淋巴瘤
• 腎癌
• 其他

癌症生物標記市場規模（按產品和複合年成長率） (2025-2032)

• 市場概覽
• 裝置
  • 影像設備
  • 基於病理學的設備
  • 切片檢查器械
• 耗材
  • 抗體
  • 套件和試劑
  • 探測
• 生物資訊軟體

癌症生物標記市場規模（按應用）及複合年成長率（2025-2032）

• 市場概覽
• 診斷
• 研究與開發
• 預後
• 風險評估
• 其他用途

癌症生物標記市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 診斷實驗室
• 與生物製藥公司的交叉關係
• 研究和學術機構
• 其他

癌症生物標記市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• F. Hoffmann-La Roche AG（Switzerland）
• Thermo Fisher Scientific Inc.（USA）
• QIAGEN NV（Germany/Netherlands）
• Agilent Technologies, Inc.（USA）
• Abbott Laboratories（USA）
• Illumina, Inc.（USA）
• Bio-Rad Laboratories, Inc.（USA）
• Myriad Genetics, Inc.（USA）
• Guardant Health, Inc.（USA）
• Exact Sciences Corporation（USA）
• Sysmex Corporation（Japan）
• Danaher Corporation（USA）
• PerkinElmer, Inc.（USA）
• DiaSorin SpA（Italy）
• BioMerieux SA（France）
• Natera, Inc.（USA）
• Adaptive Biotechnologies Corporation（USA）
• NeoGenomics, Inc.（USA）

結論和建議

Cancer Biomarkers Market size was valued at USD 27.1 billion in 2023 and is poised to grow from USD 30.49 billion in 2024 to USD 78.22 billion by 2032, growing at a CAGR of 12.5% during the forecast period (2025-2032).

The global cancer biomarker market is poised for significant growth, driven by an increasing incidence of cancer worldwide and heightened investments in oncology research. Growing awareness of the critical role of cancer biomarkers in enhancing diagnostic accuracy and treatment efficacy is expected to open new avenues for companies in this sector. Additionally, the rising trend of personalized medicine and gene therapies is anticipated to further propel the utilization of cancer biomarkers. Technological advancements coupled with a preference for non-invasive and minimally invasive methods will create further opportunities. However, challenges such as concerns over clinical validity, limited awareness among healthcare professionals, ethical issues, and stringent regulatory landscapes could constrain market progress in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Biomarkers Market Segments Analysis

Global Cancer Biomarkers Market is segmented by Profiling Technology, Cancer Type, Product, Application, End User and region. Based on Profiling Technology, the market is segmented into Omics Technology and Imaging Technologies. Based on Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkins Lymphoma, Kidney Cancer and Others. Based on Product, the market is segmented into Instruments, Consumables and Bioinformatics Software. Based on Application, the market is segmented into Diagnostics, Research and Development, Prognostics, Risk Assessment and Other Applications. Based on End User, the market is segmented into Diagnostic Laboratories, Biopharmaceutical Companies and Cros, Research and Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cancer Biomarkers Market

The rising prevalence of cancer is largely attributed to poor lifestyle choices and the widespread adoption of unhealthy habits, leading to a significant increase in the number of individuals diagnosed with the disease. This alarming trend is a primary driver for the cancer biomarkers market, as these biomarkers are essential for both cancer diagnosis and treatment. Their critical function in identifying cancer early and facilitating targeted therapies has amplified the demand for cancer biomarkers globally, reflecting the urgent need for effective diagnostic tools and treatment options in the growing battle against cancer.

Restraints in the Cancer Biomarkers Market

The Cancer Biomarkers market faces significant challenges, primarily due to concerns surrounding the privacy and ethical use of the molecular and genetic data from patients. Since cancer biomarkers provide insights that go beyond mere identification, they carry sensitive information about an individual's health. As public awareness and apprehension regarding data privacy rise, it is likely to inhibit the growth and demand for cancer biomarkers in the near future. Companies operating in this sector must navigate these issues carefully to maintain trust and foster adoption while ensuring compliance with evolving regulations related to personal health information.

Market Trends of the Cancer Biomarkers Market

The Cancer Biomarkers market is witnessing a significant trend towards the integration of artificial intelligence (AI) and machine learning technologies, revolutionizing biomarker research and diagnostics. Companies are leveraging AI to analyze extensive datasets, enabling them to uncover intricate patterns that facilitate the rapid discovery of novel cancer biomarkers. This technological advancement not only accelerates innovation but also enhances diagnostic accuracy, which is crucial for personalized medicine. As stakeholders increasingly recognize the potential of AI-driven insights, investment in these advanced technologies is expected to rise, positioning AI as a pivotal component in the advancement of cancer biomarker research and clinical applications.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Cancer Biomarkers Market Size by Profiling Technology & CAGR (2025-2032)

• Market Overview
• Omics Technology
  • Proteomics
  • Immunoassays
  • Mass Spectrometry
  • 2D gel Electrophoresis
  • Protein Microarrays
  • Others
  • Genomics
  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • In Situ Hybridization
  • Others
• Imaging Technologies
  • Ultrasound Imaging
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Positron Emission Tomography
  • Mammography

Global Cancer Biomarkers Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Leukemia
• Thyroid Cancer
• Bladder Cancer
• Non-Hodgkins Lymphoma
• Kidney Cancer
• Others

Global Cancer Biomarkers Market Size by Product & CAGR (2025-2032)

• Market Overview
• Instruments
  • Imaging Instruments
  • Pathology Based Instruments
  • Biopsy Instruments
• Consumables
  • Antibodies
  • Kits and Reagents
  • Probes
• Bioinformatics Software

Global Cancer Biomarkers Market Size by Application & CAGR (2025-2032)

• Market Overview
• Diagnostics
• Research and Development
• Prognostics
• Risk Assessment
• Other Applications

Global Cancer Biomarkers Market Size by End User & CAGR (2025-2032)

• Market Overview
• Diagnostic Laboratories
• Biopharmaceutical Companies and Cros
• Research and Academic Institutes
• Others

Global Cancer Biomarkers Market Size & CAGR (2025-2032)

• North America (Profiling Technology, Cancer Type, Product, Application, End User)
  • US
  • Canada
• Europe (Profiling Technology, Cancer Type, Product, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Profiling Technology, Cancer Type, Product, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Profiling Technology, Cancer Type, Product, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Profiling Technology, Cancer Type, Product, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Germany/Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptive Biotechnologies Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations